APNmAb005, an anti‐tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathies

Tai, C., Ma, H., Li, C., Fang Wu, M., Wang, S., Wu, C., … Navia, B. (2023). APNmAb005, an anti‐tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathies. Alzheimer’s & Dementia, 19(S21). https://doi.org/10.1002/alz.076888